Therefore, the reconstruction of immune tolerance utilizing the PD-1/PD-L1 pathway may appear to be a novel approach for the treatment of TAO and other autoimmune diseases in the future. The gene discussed is PDCD1; the disease is thromboangiitis obliterans.